Transparent Decision-making

QCI™ Interpret for Somatic Cancer

QCI Interpret for Somatic Cancer is an integrated clinical decision support solution designed specifically for routine somatic cancer testing laboratories assessing next-generation sequencing (NGS) data. With QCI you can interpret and report NGS variants in the context of over 10 million relevant biomedical findings from the QIAGEN Knowledge Base, leveraging the experience of over 16+ years in manual curation. QCI allows you to minimize complexity, time, and cost associated with determining clinical significance and action-ability of NGS variants.



Sample to Insight

Scalable insights powers growth

QCI Interpret replaces your complex and tedious clinical NGS variant research with a scalable interpretation workflow alternative that helps grow your indication menu and volume.

Key Benefits:

- Reduce the time, costs, and complexity associated with NGS tests
- Focus on actionable variants, including co-occurring alterations, to increase treatment and clinical-trial matching
- Build your own private, experience-based database with each variant assessed and reported increasing speed and accuracy with subsequent interpretations

Actionable information guides decisions

QCI is an interpretation productivity tool that helps identify actionable variants fast with results you can trust, all in one secure web application.

Key Features:

- Computed variant classification based on ACMG professional guidelines focused on actionable content from drug-labels, and clinical trials
- Manually curated clinical case counts and functional studies with digital links direct to source materials
- Report drafting with bibliographic reference citations included

Speak to us about QCI Interpret or request a demo

Find out if QCI interpret for Somatic Cancer fits your NGS interpretation and reporting needs. Speak to a representative from QIAGEN Bioinformatics to take a closer look. Request your free, no obligation, demonstration of QCI™ Interpret for Somatic Cancer today.

> "Getting from raw sequencing data to accurate and timely curation of clinically actionable variants and reporting in a user-friendly format for our ordering physicians continues to be a significant challenge for complex molecular testing. Working in collaboration with QIAGEN on the development and validation of QIAGEN's new Clinical Insight platform in support of somatic cancer testing has resulted in scalable and reproducible results in addressing our labs unmet bioinformatics needs and challenges. We look forward to continued validation work with QIAGEN and realizing the full potential of the QIAGEN Clinical Insight platform.
>
> Dr. Gregory J. Tsongalis
>
> Director of the Molecular Pathology and Translational Research Program at the Dartmouth-Hitchcock Medical Center

Contact us now at: QCI-Info@qiagen.com

Learn more online at: qiagenbioinformatics.com/QCI